07.05.2015 • TopicsCMI 05/2015businessethics

Business Ethics: Readings and Cases in Corporate Morality

Business Ethics: Readings and Cases in Corporate Morality
Business Ethics: Readings and Cases in Corporate Morality

The fifth edition of Business Ethics addresses current, intriguing, often complex issues in corporate morality through 53 readings and 30 pertinent case studies.
Significantly updated, it includes new leading articles, related current cases, and mini-cases based on MBA student dilemmas and provides impartial, point-counterpoint presentations of different perspectives on the most important and highly contended issues of business ethics. All authors have substantial experience in teaching, writing, and conducting research in the field.

Business Ethics: Readings and Cases in Corporate Morality
W. Michael Hoffman, Robert E. Frederick, Mark S. Schwartz
Wiley Blackwell
Price: 55.90 Euro
ISBN: 978-1-118-33668-7

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.